Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-02 20:47:36 - browse：5188

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of expert advisers to the Food and Drug Administration on Friday voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about the powerful treatment’s side effects.

The group voted 11-0 that the benefits of Carvykti, a CAR-T medicine from Johnson & Johnson and Legend Biotech, outweighed its risk for patients with multiple myeloma whose disease has persisted despite initial treatment. The same panel voted 8-3 in favor of Abecma, from Bristol Myers Squibb and 2seventy Bio, for multiple myeloma patients who’ve received at least two lines of therapy. Currently both medicines are approved only for patients who have been treated for myeloma with four or more medications.

In clinical trials, each drug proved to significantly delay disease progression compared to standard therapy. But zooming in on the data, the FDA observed an alarming imbalance of deaths in the early months of both studies, finding that more patients in the CAR-T group died of myeloma or side effects than those receiving the standard of care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Cheap, fast test for Zika and dengue could cost just $1

knowledge

WSS

NIH tests clinical research in primary care with $30 million program

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Thermo Fisher plant for manufacturing gene therapies to expand

CDC advisers recommend seasonal use of Pfizer RSV shot

Study: Why relieving medical debt did not improve financial outcomes

Biotech stock slump in 2023: awaiting the turnaround

knowledge

Wikipedia

leisure time

Jerome Adams on the need for new antivirals for Covid

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Hepatitis C has a cure — but many Americans still lack access to it

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

The high cost of giving birth even with insurance

STAT Virtual Event: Putting AI to the Test

What does generative AI mean for health care? We asked experts

My daughter's legacy lives on through her writing, phage therapy

Walensky prepares to leave CDC — and Congress — behind

Readers discuss the intersection of pregnancy and addiction

hotspot

Lasker Awards 2023: Winners in biomedical research

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Senators: Long

ALS patient reclaims some autonomy thanks to wearable 'robot'

knowledge

Wikipedia

knowledge

explore